RETpositive / LUNGevity Award  https://www.lungevity.org/research/translational-science-research-award-programs/applying-for-lungevity-award/2022  supports project(s) expected to have a direct impact on the outcomes of patients with advanced RET-positive lung cancer, but innovative proposals that address other unmet needs in the RET-positive lung cancer space are also invited for submission. Projects are to include at least one aim that is translational and must be directly related to improvement of patient outcomes and/or lead to a clinical trial. Projects using multikinase inhibitors will not be favorably reviewed.

The Hamoui Foundation/LUNGevity Award   https://www.lungevity.org/research/translational-science-research-award-...   supports high-impact research that seeks to transform the future for people diagnosed with RET-positive lung cancer by changing RET-positive lung cancer into a chronic or curable condition. The goal of the award is to fund impactful proposals in the RET-positive lung cancer space with direct clinical implications within 1-2 years. Projects must be directly related to improvement of patient outcomes and ideally lead to a clinical trial (if the project itself does not include a clinical trial).
 

LUNGevity Foundation Award Programs